Neuroone Medical Technologies (NasdaqCM:NMTC) Update / Briefing Transcript

NeuroOne Medical Technologies Conference Call Summary Company Overview - Company: NeuroOne Medical Technologies Corporation - Ticker: NasdaqCM: NMTC - Focus: Transforming diagnosis and treatment of neurological disorders through innovative technology in three areas: brain, pain, and drug delivery [3][4] Core Points and Arguments - Technology Advantages: The company's thin film multifunction electrode technology allows for percutaneous placement, reduced hospitalizations, fewer adverse events, and improved patient outcomes [3][4] - Product Revenue: Reported product revenues of $9.1 million for fiscal year 2025, a 163% increase year-over-year, meeting guidance of $8 to $10 million [4][9] - Strategic Partnerships: Expanded agreement with Zimmer Biomet includes exclusive distribution for the OneRF ablation system and a one-time license revenue of $3 million [5][9] - Patient Impact: Highlighted a success story of a patient, Clara, who became seizure-free after using their technology, showcasing the positive impact on quality of life [5][10] - Financial Position: Preliminary cash and cash equivalents of $6.6 million as of September 30, 2025, with no debt on the balance sheet [9][10] Development and Future Plans - Product Launches: Limited launch of the OneRF trigeminal neuralgia system expected in November 2025, with centers already lined up for cases [6][15] - Growth Strategy: Plans to support Zimmer Biomet's commercial expansion, pursue ISO 13485 clearance, and develop partnerships for drug delivery platforms [8][10] - Market Potential: The market for drug delivery and pain management technologies is expected to exceed current market participation [7][8] Additional Insights - Sales and Marketing Efforts: Increased training of sales reps from Zimmer Biomet has led to heightened interest and utilization of the technology [24][25] - Patient Awareness: Collaborations with epilepsy organizations aim to raise patient awareness about available therapies [25][26] - Reimbursement Support: The company assists physicians with reimbursement processes, although specific codes are not disclosed [26][27] - Registry Development: Efforts to establish a registry to collect and publish patient outcomes data are underway, which is critical for demonstrating the technology's effectiveness [28][29] Conclusion - Outlook: The company remains optimistic about future growth potential, emphasizing the meaningful impact of its technology on patients' lives and the successful execution of its strategic goals in fiscal year 2025 [10][34]